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Membrane type-1 matrix metalloproteinase (MT1-MMP) is a protease activating
MMP-2 that mediates cleavage of extracellular matrix components and plays piv-
otal roles in tumor migration, invasion and metastasis. Because in vivo noninva-
sive imaging of MT1-MMP would be useful for tumor diagnosis, we developed a
novel near-infrared (NIR) fluorescence probe that can be activated following
interaction with MT1-MMP in vivo. MT1-hIC7L is an activatable fluorescence
probe comprised of anti-MT1-MMP monoclonal antibodies conjugated to self-
assembling polymer micelles that encapsulate NIR dyes (IC7-1, kem: 858 nm) at
concentrations sufficient to cause fluorescence self-quenching. In aqueous buffer,
MT1-hIC7L fluorescence was suppressed to background levels and increased
approximately 35.5-fold in the presence of detergent. Cellular uptake experi-
ments revealed that in MT1-MMP positive C6 glioma cells, MT1-hIC7L showed sig-
nificantly higher fluorescence that increased with time as compared to hIC7L, a
negative control probe lacking the anti-MT1-MMP monoclonal antibody. In MT1-
MMP negative MCF-7 breast adenocarcinoma cells, both MT1-hIC7L and hIC7L
showed no obvious fluorescence. In addition, the fluorescence intensity of C6
cells treated with MT1-hIC7L was suppressed by pre-treatment with an MT1-MMP
endocytosis inhibitor (P < 0.05). In vivo optical imaging using probes intrave-
nously administered to tumor-bearing mice showed that MT1-hIC7L specifically
visualized C6 tumors (tumor-to-background ratios: 3.8  0.3 [MT1-hIC7L] vs
3.1  0.2 [hIC7L] 48 h after administration, P < 0.05), while the probes showed
similarly low fluorescence in MCF-7 tumors. Together, these results show that
MT1-hIC7L would be a potential activatable NIR probe for specifically detecting
MT1-MMP-expressing tumors.
C ancer is among the diseases with the highest morbidityand mortality rates worldwide, and a variety of basic and
clinical work has been performed to seek effective treatments
for various cancer types. To achieve effective qualitative diag-
noses, detection of biomolecules related to tumor malignancy
is highly important.(1)
Matrix metalloproteinases (MMP) are zinc endopeptidases
with 16 secreted MMP and seven membrane-associated MMP
(MT-MMP) identified to date. MMP play key roles in tissue
remodeling, organ development and wound healing.(2,3) Among
MMP family members, membrane type-1 MMP (MT1-MMP,
also called MMP-14) is known to be expressed on the surface
of tumor cells during the early stages of several cancers(4) and
has a pivotal role in tumor migration and metastasis by
participating in the remodeling of the extracellular matrix and
transmitting survival signals(5–7) that could accelerate tumor
malignancy in a wide variety of cancers. Furthermore,
MT1-MMP was recently reported to induce tumor-initiating
cell invasion under hypoxic conditions and, thereby, control
metastasis,(8) and MT1-MMP overexpression was found to
induce epithelial-to-mesenchymal transition, which is known to
be associated with tumor progression and generation of cancer
stem cells.(9) Therefore, MT1-MMP holds great promise as an
early biomarker for the diagnosis of malignant tumors.
Several imaging modalities such as PET and MRI have been
developed and used clinically. Among these, optical imaging
systems can offer convenient and safe images, having pro-
nounced spatial and temporal resolution, which are desirable
for in vivo applications in clinical and basic research.
Previously, we produced a self-quenching activatable
fluorescence probe “anti-MT1-MMP mAb-ROX, (MT1-ROX),”
and confirmed that the cellular internalization of MT1-MMP
activated MT1-ROX fluorescence, which allowed the visualiza-
tion of MT1-MMP expression in tumor cells.(10) However,
MT1-ROX emits fluorescence in the visible region
(kex = 575 nm, kem = 602 nm), which precludes its use in in
vivo imaging. In contrast, we previously developed a novel
fluorescence probe “IC7L,” a self-assembling polydepsipeptide
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polymer micelle “lactosome” that encapsulates the cyanine dye
“IC7-1”, which has fluorescence signals in the near-infrared
(NIR) region (700–1000 nm); this is optimal for in vivo imag-
ing due to the minimal light absorption, scatter and autofluo-
rescence in this region.(11) Furthermore, we found that IC7L
encapsulating high concentrations of hydrophobic polymer
(poly-L-lactate) conjugated IC7-1 (hIC7L) showed stable fluo-
rescence quenching to background levels in aqueous solution
and plasma, and fluorescence dequenching following micelle
denaturation accompanied by cellular internalization of
hIC7L.(12) Based on these findings, we planned to apply hIC7L
to design an MT1-MMP imaging probe that would allow in
vivo visualization of MT1-MMP in tumors.
In this study, we first prepared MT1-hIC7L composed of
hIC7L and an anti-MT1-MMP monoclonal antibody. We
expected that the quenched MT1-hIC7L would first recognize
MT1-MMP expressed on the surface of target tumor cells, and
then be delivered into the cell following internalization of
MT1-MMP, whereupon probe denaturation or metabolism
would result in dequenching of the encapsulated dye and sub-
sequent dye fluorescence (Fig. 1). Therefore, we evaluated the
effectiveness of the activatable system in MT1-MMP-express-
ing tumors and the potential of MT1-hIC7L as a specific imag-
ing probe for MT1-MMP-expressing tumors using in vitro
cellular uptake assays and in vivo imaging studies.
Materials and Methods
Preparation of MT1-hIC7L. All chemicals were commercially
available and of the highest purity. The amphiphilic polymer
block of the lactosome, poly(sarcosine)-b-poly(L-lactic acid)
block copolymer with 70 and 30 average degrees of polymeri-
zation on the former and latter blocks, respectively, with gly-
col capping at the N-terminus (PSar70-block-PLLA30), was
supplied by the Shimadzu Corporation (Kyoto, Japan).
Maleimide group-coupled hIC7L (maleimide-hIC7L) was
prepared as previously described. In brief, the poly(sarcosine)-
b-poly(L-lactic acid) block copolymer with 75 and 30 average
degrees of polymerization for the respective former and latter
blocks and a maleimide group coupled to the N-terminus of
the lactosome (maleimide-PSar75-block-PLLA30) (194 nmol),
PSar70-block-PLLA30 (194 nmol), and IC7-1-PLLA30 (97 nmol)
dissolved in chloroform (500 lL) were dripped into a glass
test tube. The solvent was removed under reduced pressure to
form a thin film on the tube wall. PBS (0.1 M, pH 7.4) was
then added to the test tube and heated at 82°C for 20 min. The
resulting aqueous solution was filtered through a 0.20-lm Ac-
rodisc syringe filter (Pall Corp, East Hills, NY, USA) to yield
maleimide-hIC7L.
Anti-MT1-MMP antibody was prepared as shown previously
by hybridoma methods with the epitope sequence between
295Pro and 311Asn at the hinge region of the MT1-MMP pro-
tein.(13) The specific reactivity of this antibody to MT1-MMP
was analyzed using western blotting, as described in the sup-
porting materials and shown in Fig. S1. The anti-MT1-MMP
antibody (2.5 mg ⁄mL 0.16 M borate buffer, pH 8.0) was
reacted with 2-iminothiolane (10 mg ⁄mL 0.16 M borate buf-
fer, pH 8.0) for 1 h on ice. The reactant was deoxidized by
reaction with dithiothreitol (0.3 mg ⁄2 lL) for 15 min and then
purified on a Sephadex G-50 column. The resulting anti-MT1-
MMP antibody with the thiol group was added to the malei-
mide-hIC7L and incubated for 4 h on ice with protection from
light. After incubation, cysteineHCl (158 lg) was added to
the reactant and incubated for a further 30 min. The mixture
was then purified on a Superdex 200 10 ⁄300 GL column (GE
Healthcare Japan Corporation, Tokyo, Japan) equilibrated with
PBS() at a flow rate of 0.5 mL ⁄min. The high molecular
weight fraction (retention time: 14–16 min) was collected to
obtain MT1-hIC7L. The size distribution of MT1-hIC7L was
measured at 25°C using a Zetasizer Nano-S90 (Malvern Instru-
ments Ltd, Malvern, UK). The concentration of the anti-MT1-
MMP antibody conjugated to MT1-hIC7L was measured using
a bicinchoninic acid (BCA) assay, and the number (molar
ratio) of anti-MT1-MMP antibodies per hIC7L was calculated
using estimated molecular weight values of 150 and 1315 kDa
for the anti-MT1-MMP antibody and hIC7L, respectively. The
purity was analyzed by size exclusion chromatography using a
Superdex 200 10 ⁄ 300 GL column (GE Healthcare) equilibrated
Fig. 1. Schematic illustration of the design and
strategy of MT1-hIC7L. Quenched MT1-hIC7L
first attaches to membrane type-1 matrix
metalloproteinase (MT1-MMP) expressed on tumor
cells, and is then delivered to the cell interior via
MT1-MMP internalization whereupon fluorescence
signals are emitted following probe degradation.
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with PBS at a flow rate of 0.5 mL ⁄min. Absorbance at 215
and 830 nm was used to detect the lactosome and IC7-1,
respectively, which confirmed that the absorbance peaks at
both wavelengths were detected simultaneously in the high
molecular weight fraction. The affinity of MT1-hIC7L for
MT1-MMP was evaluated by flow cytometry using methods
similar to those described previously (Data S1 and Fig. S2).(14)
Optical properties of MT1-hIC7L. MT1-hIC7L (1 mg ⁄mL,
100 lL) was incubated in 100 lL PBS (0.1 M, pH 7.4) with
or without SDS (5% final concentration) for 30 min at room
temperature. After incubation, 0.8 mL PBS was added to the
solution and fluorescence images were acquired using a Clairv-
ivo OPT (Shimadzu Corporation) with a 785-nm laser diode
for excitation and a 845 ⁄55-nm band path filter for emission.
The fluorescence emission spectra were also measured with a
fluorescence spectrometer (Fluorolog-3; HORIBA Jobin Yvon
Inc, Kyoto, Japan) following excitation at 815 nm using a slit
width of 5 nm for both excitation and emission measurements.
Cellular uptake study. C6 glioma cells (HSRRB, Tokyo,
Japan) (MT1-MMP high-expressing tumor cells) and MCF-7
human breast adenocarcinoma cells (ATCC, Manassas, VA,
USA) (MT1-MMP low-expressing cells) were cultured in
DMEM medium with 10% FBS at 37°C in a humidified atmo-
sphere containing 5% CO2.
(10) After pre-incubation of cells
(2 9 105 cells) overnight in 24-well poly-D-lysine-coated
dishes (Biocoat, Becton Dickinson, San Jose, CA, USA), probes
(40 lg ⁄1 mL DMEM with 50 lM BSA) were added and incu-
bated at 37°C in a humidified atmosphere containing 5% CO2.
At 30 min, 1, 3 and 6 h, the cells were washed twice with PBS
and fluorescence images were acquired using a Clairvivo OPT
with a 785 nm laser diode for excitation and a 845 ⁄55 nm band
path filter for emission. After image acquisition, the cells were
treated with 0.2 N NaOH and the cell lysate protein concentra-
tions were measured by BCA assay. The fluorescence intensity
of the cells was analyzed using Clairvivo OPT display software
version 2.60. The fluorescence intensity of the cells was repre-
sented as a ratio to the dosage as follows:
FI Ratio ¼
½Fluorescence Intensity of the cells
½Fluorescence Intensity of the probe added to the cells  ½Cell lysate (mg protein)
For the blocking study, C6 cells were treated with type I
collagen (Col I; 100 lg ⁄ 1 mL DMEM) for 24 h at 37°C. The
cells were washed twice with PBS, and then MT1-hIC7L
(40 lg ⁄1 mL DMEM with 50 lM BSA) was added. After
incubation for 30 min, 1, 3 and 6 h, cells were washed twice
with PBS. Subsequent fluorescence measurements were carried
out as described above.
Preparation of tumor bearing mice. Female nude mice
(BALB ⁄ c nu ⁄nu) and female SHO mice (SHO-PrkdcscidHrhr)
supplied by Japan SLC Inc (Hamamatsu, Japan) and Charles
River Laboratories Japan (Yokohama, Japan) respectively,
were housed under a light : dark 12:12 h cycle and given free
access to food and water. The animal experiments performed
in the present study were conducted in accordance with institu-
tional guidelines and approved by the Kyoto University Ani-
mal Care Committee, Japan. C6 cells (5 9 106 cells in
100 lL) were subcutaneously inoculated into the right hind
legs of 4-week-old female nude mice (BALB ⁄ c nu ⁄nu), and an
in vivo imaging study was performed after a 2-week growth
period. For preparation of MCF-7 xenografted mice, 5-week-
old female SHO mice were first implanted subcutaneously with
a 0.72-mg 60-day release 17-estradiol pellet (Innovative
Research of America, Toledo, OH, USA). The next day, MCF-
7 cells (1.0 9 107 cells) suspended in 100 lL PBS containing
50% Geltrex were subcutaneously inoculated into the left hind
legs. Six weeks after transplantation, the MCF-7 tumor-bearing
mice were used for the following imaging study. The MT1-
MMP expression levels in C6 and MCF-7 xenografted tumors
were also evaluated by western blotting and immunohisto-
chemical methods, as described in Data S1, and the results are
shown in Fig. S3.
In vivo imaging study. MT1-hIC7L or hIC7L (2 mg ⁄mL
PBS, 100 lL) were injected into tumor-bearing mice through
the tail vein and NIR fluorescence images were collected using
a Clairvivo OPT with a 785-nm laser diode for excitation, and
a 845 ⁄55-nm band path filter for emission. During the imaging
process, mice remained on the imaging stage under anesthesia
using 2.5% isoflurane gas in oxygen (1.5 L ⁄min). Regions of
interest (ROI) were designated for the tumor and background
(around the neck) on the acquired images to measure fluores-
cence intensities.
Statistics. Data are represented as the mean  SD. Statistical
analyses were performed with two-way factorial ANOVA fol-
lowed by a Tukey–Kramer test. A two-tailed value of
P < 0.05 was considered to be statistically significant.
Results
Probe preparation and determination of optical properties. The
particle sizes of MT1-hIC7L and hIC7L were 44.9  1.7 nm
(n = 3) and 35.1  0.4 nm (n = 3), respectively. The pre-
sumed average molar ratio of anti-MT1-MMP antibody conju-
gated to hIC7L was 1.4  0.1 (n = 3). The immunoreactivity
of MT1-hIC7L relative to MT1-MMP as measured by flow
cytometry was slightly decreased compared to the anti-MT1-
MMP antibody but was higher than for the control groups
treated with only PBS (Fig. S2).
MT1-hIC7L fluorescence was suppressed to background lev-
els in aqueous buffer (PBS), and increased in SDS solution
(Fig. 2a). The fluorescence intensity was also quantified from
the images and the ratio of the intensity in SDS solution com-
pared to that in PBS was 35.5  6.2. The fluorescence spec-
trum of MT1-hIC7L was also apparent in SDS solution but not
in PBS (Fig. 2b).
In vitro study. MT1-hIC7L fluorescence in C6 cells, which
have high MT1-MMP expression levels, increased gradually
and was significantly higher than that of hIC7L 3 h or more
after addition (Fig. 3a). In contrast, probe uptake by MCF-7
cells (low MT1-MMP expression levels) was consistently low
for both probes (Fig. 3b). When cells were pretreated with the
endocytosis inhibitor Col I, the fluorescence intensity of cells
incubated with MT1-hIC7L was significantly depressed com-
pared to that of the non-pretreated group (Fig. 3c).
In vivo imaging study. Compared to the hIC7L administered
group, in MT1-hIC7L administered mice the fluorescence
gradually increased in C6 xenografted tumors, which could be
imaged clearly at 24 and 48 h post-administration (Fig. 4a). In
addition, the T ⁄B ratios of MT1-hIC7L increased with time
and provided higher values than those of hIC7L (Fig. 4c,
3.2  0.3 vs 2.7  0.2 at 24 h, and 3.8  0.3 vs 3.1  0.2 at
48 h). In mice xenografted with MCF-7 cells which express
low levels of MT1-MMP, there was no significant difference
in the images between the MT1-hIC7L-administered and
hIC7L-administered groups throughout the study duration
(Fig. 4b). The T ⁄B ratios in the MCF-7 tumors were
© 2014 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd
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unchanged regardless of the probe used (Fig. 4d, 2.5  0.3 vs
2.6  0.2 at 24 h, and 2.8  0.4 vs 3.0  0.2 at 48 h).
Discussion
In the present study, we developed MT1-hIC7L as an optical
activatable probe for MT1-MMP detection. MT1-hIC7L fluo-
rescence was effectively quenched in aqueous buffer, and then
dramatically activated under micelle-degenerating conditions
(Fig. 2) and in cells expressing high levels of MT1-MMP
following MT1-MMP-dependent internalization (Fig. 3). In
addition, high fluorescence levels were observed in MT1-
MMP-expressing tumors in xenografted mice 24 and 48 h after
MT1-hIC7L administration (Fig. 4).
In the cell uptake study, MT1-hIC7L showed fluorescence
increasing with time only in C6 cells but continuously low
fluorescence in MCF7 cells. The similar result obtained in
another cell line that expresses high levels of MT1-MMP
(HT1080 human fibroblastoma cells [Fig. S4]) coupled with the
lack of significant hIC7L fluorescence regardless of the cells
used, suggests that MT1-hIC7L dequenching was successfully
achieved following specific interactions with MT1-MMP. Fur-
thermore, we performed an inhibition study with Col I, an inhib-
itor of dynamin-dependent MT1-MMP internalization,(15) and
found that the C6 cell fluorescence of the MT1-hIC7L-treated
group was significantly decreased by Col I pre-treatment. The
moderate fluorescence that was observed in the Col I pre-treated
MT1-hIC7L group might be due to other MT1-MMP internali-
zation processes, such as clathrin-independent mechanisms
involving caveolae.(6,16) Nonetheless, the results indicate that
the fluorescence activation of MT1-hIC7L in the MT1-MMP
high expressing tumor cells was primarily dependent on MT1-
MMP internalization.
In the in vivo study, significantly higher fluorescence was
observed in C6 tumors in mice after MT1-hIC7L administra-
tion as compared with other groups. However, it should be
noted that measurable fluorescence was observed in tumors of
the hIC7L-administered groups, which was similar to our pre-
vious study with the fluorescent lactosome probe “IC7L” (T ⁄B
ratios for IC7L: 2.6  0.4 at 24 h, and 3.1  0.3 at 48 h).(11)
Therefore, considering that quenched hIC7L still had weak flu-
orescence that was gradually dequenched in blood while still
retaining its micelle structure,(12) the tumor fluorescence in
hIC7L administered groups might reflect the lactosome biodis-
tribution. In contrast, we previously reported that targeting
ligands such as antibodies conjugated on the surface of lacto-
some would have negligible effects on the amount of lacto-
some probe delivered to tumor tissues because lactosomes are
originally delivered to tumors at high levels by enhanced per-




Fig. 2. Optical characteristics of activatable type
IC7-1 lactosomes. (a) Fluorescence images of MT1-
hIC7L after incubation in PBS buffer (i) or 5% SDS
solution (ii) for 30 min. (b) Fluorescence emission
spectrum of MT1-hIC7L after incubation in PBS
buffer (blue) or 5% SDS solution (red) for 30 min.
(a) (b) (c)
Fig. 3. Cell uptake of MT1-hIC7L. (a,b) C6 (a) or MCF-7 cells (b) were treated with MT1-hIC7L or hIC7L and the fluorescence intensities were
acquired for 6 h. Data are expressed as the FI ratio (mean  SD) for 4 samples. Comparison between the MT1-hIC7L- and hIC7L-treated groups
was performed with two-way factorial ANOVA followed by Tukey–Kramer test (*P < 0.01 vs hIC7L). (c) The mean fluorescence intensity of C6 cells
treated with (dotted line) or without Col I (solid line) for 6 h at 0.5, 1, 3 and 6 h after incubation with MT1-hIC7L. Data are expressed as%Inten-
sity ⁄ mg protein (mean  SD) for 4 samples. Comparisons between the Col I-treated (Col I [+]) and Col I-untreated groups (Col I []) were per-
formed with two-way factorial ANOVA followed by the Tukey–Kramer test (*P < 0.05 vs Col I [+]).
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difficulties in target biomolecule-specific in vivo imaging.(12)
Therefore, in this study MT1-hIC7L could achieve MT1-
MMP-specific in vivo imaging due to the combination of the
fluorescence activatable hIC7L system and active targeting
delivery system with the anti-MT1-MMP antibody, which
enables probe internalization.
While MT1-hIC7L could visualize MT1-MMP-expressing
tumors both in vitro and in vivo, non-specific fluorescence
accumulation was observed in tumors of hIC7L-treated mice.
Because nanocarriers with neutral or positive surface charges
are known to cause non-specific cell internalization, as was
reported in in vitro studies,(17,18) the surface charge of MT1-
hIC7L (estimated to be 0.5 mV) might not be sufficiently
negative to avoid non-specific cellular uptake in tumors, espe-
cially during the delayed phase after administration. In addi-
tion, the non-specific dequenching of hIC7L in the blood or
tumor tissue might occur because of the relatively low probe
stability in the blood. To address these issues, we are now try-
ing to improve the probe presented in this study by modifying
the hydrophilic moiety of the block polymer to modulate the
surface charge, and by conjugating a D-lactate polymer to the
NIR fluorophore to form a stereocomplex that is known to
slow the degradation rate of the micelle complex due to its
higher crystallinity.(19)
In this study, we chose the “lactosome” to be the optical probe
core because of its suitable biodistribution, bioavailability and
structure that allows for control of the resulting optical signals.
Lactosomes have a favorable size (diameter: 30–40 nm) for
delivery to tumor tissue through the EPR effect,(20) and can
escape the reticuloendothelial system that can cause nonspe-
cific accumulation of the probes in the abdominal region.(21) In
addition, due to the composition of the biodegradable sub-
stances poly-sarcosine and poly-L-lactic acid, lactosomes have
low toxicity, which is a point of concern for inorganic com-
pounds such as quantum dots(22) and gold nanorods.(23–25) Fur-
thermore, lactosomes have narrow hydrophobic cores in which
lipophilic dyes may be encapsulated to high concentrations,
which allows the formation of self-quenching states without
affecting other probe qualities such as biodistribution. Com-
pared with other fluorescence activatable systems such as pho-
toinduced electron transfer (PeT) and F€orster resonance energy
transfer (FRET), self-quenching is preferable for its optical
wavelength ranges around 800–900 nm where controlling opti-
cal signal can be difficult with PeT and FRET systems.(26,27)
Therefore, the lactosome probe with its self-quenching activat-
able system appears to be a promising tool for noninvasive in
vivo diagnostic techniques.
Several MT1-MMP dependent activatable optical probes that
rely on the enzymatic activity of MT1-MMP and use the
FRET system have been reported.(28,29) Whereas MT1-MMP
internalization has been reported to play an important role in
tumor cell migration and invasion,(6,16,30) there are no reports
on probes that enable in vivo visualization of MT1-MMP inter-
nalization. Therefore, MT1-hIC7L activated by MT1-MMP
internalization would provide additional valuable information
for elucidating MT1-MMP functions in tumors. Furthermore,
multicolor in vivo optical imaging is also emerging as a prom-
ising technique and can detect a variety of functions simulta-
neously.(31) The MT1-hIC7L fluorophore is IC7-1, which has
absorption and emission wavelengths at 800–900 nm that are
suitable for in vivo optical imaging, and offers fluorescence
characteristics that differ significantly from commercially
available or reported optical probes.(32) Therefore, we expect
that the multicolor in vivo imaging with MT1-hIC7L and other
reported FRET-type MT1-MMP imaging probes would offer
further information to better understand the complicated role
and relationship of MT1-MMP internalization with its enzyme
activity in tumor tissue.
From a clinical standpoint, optical imaging technology has
been rapidly advancing in terms of molecular probes as well
as imaging modalities such as endoscopic cameras(26) and
clinical breast scanners,(33) and is expected to provide an
(a) (b)
(c) (d) Fig. 4. In vivo imaging of MT1-hIC7L. (a,c)
Fluorescence images of C6 cell xenografted mice (a)
or MCF-7 xenografted mice (c) at 0 h (just after
injection), 12, 24 and 48 h after administration of
MT1-hIC7L (upper) and hIC7L (lower). Arrows
indicate the tumor tissue. (b,d) The C6 tumor (b) or
MCF-7 tumor (d) -to-background (T ⁄ B) fluorescence
intensity ratios obtained from the region of interest
of the tumor and background (neck) of mice
administered MT1-hIC7L and hIC7L. Data are
expressed as T ⁄ B ratio (mean  SD). Comparison of
the T ⁄ B ratios of MT1-hIC7L- and hIC7L-
administered groups was performed with two-way
factorial ANOVA followed by the Tukey–Kramer test
(*P < 0.05 vs hIC7L).
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informative navigation aid for surgical techniques.(34) In such
image-guided surgery, NIR probes would be desirable due
to their ability to discriminate between structures that are to
be resected (e.g. tumor tissue) and spared (e.g. vessels or
lymph node). Because NIR fluorescence can strongly pene-
trate through biological tissue, NIR-based probes would
be useful for locating embedded structures.(35) As such,
MT1-hIC7L would also be a clinically powerful tool for the
diagnosis of tumor malignancy by specifically detecting
MT1-MMP.
In summary, we developed MT1-hIC7L, which shows self-
quenched fluorescence and specifically interacts with MT1-MMP
expressed on tumor cells that internalize the probe, allowing the
fluorescence to be dequenched after lactosome degeneration.
These results indicate that MT1-hIC7L would be a useful NIR
probe for specific imaging of MT1-MMP-expressing tumors.
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Supporting Information
Additional supporting information may be found in the online version of this article:
Fig. S1. Western blotting analysis of the membrane type-1 matrix metalloproteinase (MT1-MMP) specific binding affinity of anti-MT1-MMP
mAb used as a ligand of MT1-hIC7L.
Fig. S2. Flow cytometric analysis of MT1-hIC7L and anti-MT1-MMP antibody binding to membrane type-1 matrix metalloproteinase (MT1-
MMP)-expressing cells.
Fig. S3.Western blotting and immunohistochemical analysis of the membrane type-1 matrix metalloproteinase (MT1-MMP) expression levels in
C6 and MCF-7 xenografted tumor tissues.
Fig. S4. Uptake of MT1-hIC7L by HT1080 human fibroblastoma cells.
Data S1. Methods for western blotting flow cytometry, immunohistochemistry and cellular uptake of MT1-hIC7L.
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